Table 2.
Clinical trials evaluating new therapies against FGF/FGFR axis in different tumors.
| Cancer Type | First Author | Title | Therapeutic Treatment | References |
|---|---|---|---|---|
| Gastric/Gastric-oesophageal | Wainberg et al. (2022) |
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study | Treatment with Bemarituzumab effectively inhibits the pathway of FGF and FGFR. | [218] |
| Bile ducts | Bibeau et al. (2022) |
Progression-Free Survival in Patients with Cholangiocarcinoma with or Without FGF/FGFR Alterations: A FIGHT-202 Post Hoc Analysis of Prior Systemic Therapy Response | Patients with an alteration of FGFR showed a more prolonged progression-free survival during treatment with Pemigatinib and an association with second-line treatment. | [214] |
| Prostate | Liow et al. (2022) |
Phase 2 Study of Neoadjuvant FGFR Inhibition and Androgen Deprivation Therapy Prior to Prostatectomy | The study showed the effects of FGF/FGFR-signaling inhibition and acute androgen deprivation. | [219] |
| Bile ducts, breast, colon, head and neck, other solid tumors | Subbiah et al. (2022) |
FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies | Pemigatinib has been shown to be clinically and pharmacodynamically safe; it is also safe towards tumors due to FGFR mutation. | [215] |
| Lung | Aggarwal et al. (2022) |
SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients with Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy) | Treatment with AZD4547 showed a safe profile but unfortunately a modest improvement in patients with FGFR mutations. | [213] |
| Prostate | Choi et al. (2018) |
Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05) | This study evaluated the progression-free survival and then the safety profile of dovitinib in patients who demonstrated different alterations of FGF and VEGF receptors. | [220] |
| Endometrial | Konecny et al. (2015) |
Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study | Evaluation of the safety and activity of dovitinib, FGFR, VEGFR, PDGFR-β, and c-KIT inhibitors in patients presenting and not presenting alterations of these receptors. | [217] |
| Renal | Kim et al. (2011) |
Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma | The study reported that the tolerable dose of dovitinib effective in inhibiting the FGFR family was 400 mg/d. | [221] |
| Bile ducts | Goyal et al. (2023) |
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma | Futibatinib has proven to be a valuable treatment for patients with FGFR2 abnormalities with cholangiocarcinoma. | [216] |
| Glioblastoma | Lee et al. (2019) |
Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma | The aim of the study was to evaluate patient 3-month progression-free survival, overall survival, and safety with bevacizumab-resistant GBM. | [222] |